Clinical trials of TCR-T for HCC are currently underway to confirm its efficacy by examining AFP expression and T cell infiltration in biopsy tissues and closely monitoring biochemical markers in the liver (NCT03132792; NCT02686372; NCT02719782; NCT04677088). Here, AFP is linked to hepatocellular carcinoma.